Management of Chest Pain in CKD Stage V Patients

Diagnostic Approach

The American College of Cardiology recommends that patients with CKD Stage V presenting with chest pain should be investigated and treated according to the same protocols used for patients without CKD, including immediate 12-lead ECG, standard acute coronary syndrome evaluation, and aggressive cardiac workup without prejudice based on their kidney disease 1, 2, 3
Obtain a 12-lead ECG immediately to evaluate for ischemic changes, as myocardial ischemia is the most frequent serious cause of chest pain in advanced CKD 1, 2, 3
Interpret troponin elevations with caution but do not dismiss them—while troponins may be chronically elevated in CKD Stage V due to reduced clearance and chronic left ventricular wall stress, rising trends in the context of chest pain indicate acute coronary syndrome until proven otherwise 1, 2, 3
Interpret BNP/NT-proBNP with caution as these are inversely associated with GFR, but elevations still correlate with left ventricular hypertrophy and dysfunction even in CKD 2

All CKD Stage V patients should be considered at exceptionally high risk for cardiovascular disease, with rates of coronary death or nonfatal MI exceeding 10 per 1,000 patient-years in those over age 50 1, 6

Follow standard acute coronary syndrome protocols per ACC/AHA guidelines without modification based on kidney disease status 1, 2, 3
Initiate antiplatelet therapy (aspirin as first-line agent) unless bleeding risk clearly outweighs cardiovascular benefit 1, 2
Proceed with cardiac catheterization and revascularization when indicated—do not withhold interventional procedures based solely on CKD status 1, 3
Adjust all renally-excreted medications for GFR <30 mL/min/1.73 m² 1, 3
Discontinue metformin in CKD Stage V (GFR <30 mL/min/1.73 m²) 1, 3
Monitor potassium and kidney function closely when using ACE inhibitors, ARBs, or aldosterone antagonists for heart failure or ischemic heart disease 1, 2, 3

Consider statin therapy for patients age >50 years with CKD Stage V not yet on dialysis, as cardiovascular event rates exceed 10 per 1,000 patient-years in this population 6
Continue antiplatelet therapy for secondary prevention unless contraindicated 1, 2
Increase frequency of potassium and kidney function monitoring with any escalation in cardiac therapy, particularly with RAAS blockade 1, 2, 3

Do not attribute elevated troponins solely to CKD—evaluate trends and clinical context, as elevations in the setting of chest pain warrant full acute coronary syndrome evaluation 2, 3
Do not withhold standard cardiac interventions based on kidney disease status—the level of care for ischemic heart disease should not be prejudiced by CKD 1, 2, 3
Do not use dual RAAS blockade due to excessive hyperkalemia and AKI risk—maintain vigilant monitoring if single-agent RAAS blockade is used 2
Do not prescribe herbal remedies in CKD Stage V patients 1, 3